Ask My Investor AI
Public company · NYSEPublished company research
XYL

Identity verified against SEC EDGAR filing 0001524472-26-000012; registered as Xylem Inc., CIK 0001524472.

Xylem Inc.

Xylem is a diversified water-technology company with direct PFAS treatment capability inherited and expanded through Evoqua. Official materials document pilot testing, permanent and mobile systems, multiple treatment media and named utility deployments, while Q1 2026 revenue was $2.125 billion. PFAS-specific orders, revenue, margins and utilization are not disclosed, so direct capability does not establish theme-specific financial materiality. The subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
XYL
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0001524472
Investment case

How this company captures the theme economics

Competitive position

Xylem combines treatment design, media-agnostic adsorption systems, mobile response and lifecycle service. Its Orange County deployment uses 30 systems capable of treating up to 86 million gallons per day, and the company states it has installed more than 40 PFAS systems nationwide. Those are issuer claims at project level, not a disclosed PFAS financial segment.

Scarce assets

Scarce assets in this value chain include accredited pfas laboratory capacity (low-ppt lc-ms/ms analysis) as monitoring mandates scale to 2027, pfas-selective ion-exchange resin supply and regeneration capability (claimed 30-40% lifecycle-cost advantage over gac), rcra-permitted high-temperature incineration capacity with validated otm-50/method 0010 emissions performance - concentrated in very few operators.

Products, segments, and customers

Xylem reports Water Infrastructure, Applied Water, Measurement and Control Solutions, and Water Solutions and Services. PFAS treatment is delivered through Evoqua-derived Water Solutions and Services capabilities including pilot, mobile, emergency and permanent adsorption systems.

Theme capture

Direct PFAS treatment capability and named deployments are verified. PFAS economics are embedded in broader water businesses and are not separately disclosed, so materiality fails closed.

Conditions

What must be true

  1. Review Xylem 10-K/investor materials for treatment-segment orders and any PFAS pipeline commentary; track OCWD-style municipal awards and mobile-fleet utilization.
  2. The exposure described for Xylem must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the PFAS treatment, destruction and liability transfer brief
Theme materiality

2 mapped themes

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Water-treatment platform spanning municipal and industrial PFAS treatment: GAC, ion-exchange, adsorption and RO systems, delivered as permanent installations and mobile/emergency units (Evoqua heritage).

PFAS treatment, destruction and liability transfer

Direct treatment capability with named municipal and mobile deployments. Official sources describe 30 Orange County systems with up to 86 MGD capacity and a portfolio spanning pilot, mobile, emergency and permanent treatment, but PFAS revenue and backlog are not disclosed.

Evidence
Xylem's PFAS guide and Orange County case study directly support capability, system count and treatment capacity; FY2025 filing and Q1 2026 results support company scale. No reviewed source isolates PFAS economics.
Materiality
not assessed — Capability and projects are verified, but PFAS revenue, orders, margins, utilization and backlog are not separately disclosed.
Water treatment technology platform (pumps, treatment, measurement, water solutions & services incl. reuse).

Wastewater as a resource-recovery platform

High and direct at the platform level. Xylem is a leading global water technology company (FY2025 revenue USD 9.035bn, +5% organic) whose Water Solutions & Services segment (USD 2.464bn, +5% organic) explicitly includes recycle/reuse offerings; it is broadly exposed to reuse, advanced treatment and measurement demand.

Evidence
FY2025 revenue and Water Solutions & Services segment figures confirmed from Xylem's Q4/FY2025 results press release (src-04). Reuse/recycle inclusion in that segment is confirmed by Xylem materials surfaced in search; theme-pure revenue is not separately disclosed.
Materiality
estimated — Segment revenue is disclosed and clearly relevant, but the specific wastewater-resource-recovery portion is embedded within a broad segment and not separately reported.
Financial evidence

Official SEC filing evidence

Reference period: FY2025 and Q1 2026.

  • Revenue$9.04 billion
    FY2025[1]
  • Revenue growth0.1%
    FY2025[1]
  • Operating income$1.22 billion
    FY2025[1]
  • Operating margin0.1%
    FY2025[1]
  • EBITDA$1.80 billion
    FY2025[1]
  • Diluted EPS$3.92
    FY2025[1]
  • Operating cash flow$1.24 billion
    FY2025[1]
  • Total debt$1.94 billion
    FY2025 year-end[1]
  • Revenue$2.125 billion
    Q1 2026[2]
  • Diluted EPS$0.79
    Q1 2026[2]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

  • Finalized partial rescission removes four of six regulated compounds, shrinking treated-compound scope and some testing/treatment demand
  • Compliance-deadline extension to 2031 (or further slippage) defers utility capex and pressures near-term equipment and media orders

Thesis-break conditions

  • Final rule or court decision rescinds, vacates or raises the PFOA/PFOS MCLs above 4.0 ppt
  • Compliance deadline extended beyond April 2031 or exemptions made effectively open-ended
Investability conclusion

Where the evidence lands

NOT_READY. Official filing and issuer evidence verify identity, current company scale and direct PFAS treatment capability. PFAS-specific economics, current licensed valuation and human reviewer acceptance remain unresolved; no subject acceptance or recommendation is permitted.

Next diligence

  1. Review Xylem 10-K/investor materials for treatment-segment orders and any PFAS pipeline commentary; track OCWD-style municipal awards and mobile-fleet utilization.
  2. Quantify reuse/recovery and advanced-treatment revenue and backlog within Water Solutions & Services and Water Infrastructure; assess Evoqua integration contribution and PFAS-treatment pipeline.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Xylem Inc. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-25 · accessed 2026-07-22
  2. Xylem Reports First Quarter ResultsXylem Inc. · primary · published 2026-04-28 · accessed 2026-07-29
  3. PFAS Resource GuideXylem Inc. · primary · published undated · accessed 2026-07-29
  4. Orange County Water District Removes PFAS With 30 SystemsXylem Inc. · primary · published undated · accessed 2026-07-29